60
Participants
Start Date
January 15, 2017
Primary Completion Date
December 13, 2017
Study Completion Date
December 13, 2017
Single GamTBvac vaccination (0.25 dose)
Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
Placebo administration
Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
Double GamTBvac vaccination (0.25 dose)
Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
Double GamTBvac vaccination (0.5 dose)
Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
Double GamTBvac vaccination (1.0 dose)
Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
Sechenov First Moscow State Medical University, Moscow
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
OTHER